iSchemaView, NeuroLogica partner for stroke care
advertisement

iSchemaView, NeuroLogica partner for stroke care

par Thomas Dworetzky, Contributing Reporter | January 23, 2019
Business Affairs
A partnership has been announced to bring iSchemaView's RAPID imaging platform to Samsung subsidiary NeuroLogica’s portable CereTom CT scanners for use in mobile stroke units and ICUs.

“This is a new frontier in stroke care. We are bringing state-of-the-art technology directly to patients, no matter where they are. This allows us to make fast, accurate assessments of their clinical status and provide effective treatment directly in the MSU, or transport the patient to the appropriate hospital for expedited clot removal,” Dr. James Grotta, director of the Mobile Stroke Unit Consortium and director of Stroke Research for the Clinical Institute for Research and Innovation at the Memorial Herman–Texas Medical Center, said in a statement.

The agreement will permit the option of RAPID advanced imaging on CereToms in more than 500 ICUs worldwide, according to Dr. Anil Singhal, senior vice president of Worldwide Operations at iSchemaView.

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

The 8-slice mobile CereTom CT scanner offers high-quality, non-contrast CT, CT angiography and CT perfusion scans in a variety of patient locations. RAPID, according to the statement, “is the most advanced, fully-automated, and only clinically proven stroke imaging platform available,” and offers “intuitive and easily interpretable real-time views of brain perfusion, and allows clear visualization of the cerebral arteries.”

This assessment in MSUs equipped with both CereTom and RAPID technologies, “will be able to swiftly identify the right course of action – on-site treatment with clot-busting agents or appropriate hospital transport for thrombectomy – thereby optimizing outcomes and quality of life,” noted David Webster, chief operating officer at NeuroLogica.

RAPID won FDA approval in January for an application to the endovascular thrombectomy procedure.

“The addition of thrombectomy clearance makes RAPID even easier to use, especially by facilities and physicians with less expertise interpreting advanced imaging,” Singhal told HCB News at the time. “The flag, 'Patient meets imaging criteria for Thrombectomy' along with the clinical maps, simplifies the triage of these patients to the right center for the right treatment. RAPID results are ready in less than 2 minutes on the physician's phone via email and mobile app, as well as sent to the hospital's PACS.”

The RAPID platform uses an artificial intelligence framework consisting of expert feature extraction and proprietary algorithms to support its offerings, including CT perfusion; MR diffusion and perfusion; CT angiography; and CT ASPECT scoring. It also allows for custom notifications, custom thresholding and hypoperfusion, as well as cerebral blood volume indexes and golden hour thresholds.

You Must Be Logged In To Post A Comment